Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?
PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.
详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
JAK2 is a constitutive protein tyrosine kinase (PTK) which can activate JAK-STAT signaling.
JAK2是一种组成性酪氨酸激酶，能激活JAK - STAT信号传导途径。
Objective: to review the progress in the research of tyrosine kinase inhibitors in recent years.
目的：对近年来酪氨酸激酶抑制剂的研究进展作以综述。
Binding of FLT3L to its cognate tyrosine kinase receptor, FLT3, activates STAT3 and STAT5 (1, 3).
FLT3L结合到与它同源的酪氨酸激酶的受体FLT3结合激活STAT3和STAT 5 (1,3)。
Secondary FLT3-TKD mutations are associated with treatment failure with tyrosine kinase inhibitors.
继发性FLT3 - TKD突变与酪氨酸激酶抑制剂治疗失败有关。
HNMPA-AM3 -the insulin receptor tyrosine kinase inhibitor could block the anti-apoptosis effect of insulin.
胰岛素受体自身酪氨酸磷酸化抑制剂一一HNMPA一AM3可以阻断胰岛素的抗凋亡作用。
ObjectiveTo study the abnormity and clinical value of tyrosine kinase signaling pathway in lung adenocarcinoma.
目的探讨肺腺癌患者酪氨酸激酶传导通路的异常和临床预后的关系。
Objective: to establish a method of detecting insulin receptor tyrosine kinase (IRTK) activity from erythrocytes.
目的：建立红细胞胰岛素受体酪氨酸蛋白激酶(IRTK)的活性测定法。
Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma.
目的：研究散发型甲状腺髓样癌酪氨酸激酶受体基因（RET）的突变情况。
Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience.
大量的临床经验：酪氨酸激酶抑制剂治疗患有分化型甲状腺癌的患者：M。D。安德森经验。
The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK).
目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
CONCLUSION GST can block L-type calcium channel activity in guinea-pig colon smooth muscle cells via tyrosine kinase pathway.
结论GST可通过酪氨酸激酶途径抑制豚鼠结肠平滑肌l型钙通道。
The drugs work by preventing an enzyme called tyrosine kinase from launching a signaling cascade that fuels tumor cell growth.
这些药物的作用机制是阻断酪氨酸激酶启动信号级联反应，后者可以促进肿瘤细胞生长。
The family of ErbB tyrosine kinase receptors can transmit signals derived from growth factor of epidermal growth factor family.
属于酪氨酸激酶受体，可以传递表皮生长因子家族的信号。
Conclusions: the change of protein tyrosine kinase activity is involved in the differentiation of K562 cells induced by matrine.
结论：在苦参碱诱导K562细胞分化的过程中，涉及到蛋白酪氨酸激酶的活性改变。
Genistein, a natural tyrosine kinase inhibitor, has been reported to inhibit growth and induce apoptosis of various Turner cells.
金雀异黄素是一种天然的酪氨酸激酶抑制剂，可以抑制多种肿瘤细胞的增殖，并诱发细胞凋亡。
Objective to investigate the change of insulin receptor tyrosine kinase (TK) activity in the pathogenesis of insulin resistance (IR).
目的探讨胰岛素受体酪氨酸激酶(TK)活性变化在胰岛素抵抗(IR)发生中的作用。
I think there are several tyrosine kinase activators already developed however I am not sure that they can perform better than insulin.
我认为一些酪氨酸激酶活化剂已经出现，但是我不确信它们要比胰岛素的效果好。
In many inflammatory diseases such as septic shock (9), and psoriasis (10) the change in protein tyrosine kinase activity has been shown.
在许多炎症性疾病，如感染性休克(9)，与银屑病(10)，酪氨酸蛋白激酶的活动会表现出变化。
AIM: To explore the relationship of methylation status and expression of spleen tyrosine kinase (Syk) gene in colorectal cancer cell lines.
目的：探讨结直肠癌细胞中脾酪氨酸激酶基因甲基化和表达的关系。
Vascular epithelial growth factor binding with its receptor leads to cell proliferation and new vascular formation by tyrosine kinase pathway.
血管内皮细胞生长因子与其受体结合后通过酪氨酸激酶途径引起细胞的增殖及新生血管形成。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies.
本发明涉及治疗抗酪氨酸激酶抑制剂疗法的EGFR介导的疾病，特别是癌症。
Objective: to study Somatic mutation of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR gene) in lung adenocarcinoma patients.
目的：探讨表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞在肺腺癌患者中突变的相关因素。
Objective: to study Somatic mutation of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR gene) in lung adenocarcinoma patients.
目的：探讨表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞在肺腺癌患者中突变的相关因素。
应用推荐